Stocks on Tech Trader

Summary:

MRK has broken lower on a failed kidney cancer trial readout and sits in a weak short-term downtrend right into earnings next week, so we're staying on the sidelines.

The sharp drop on 4/21 to the low 112s came on real volume after the LITESPARK-012 study missed its endpoints, a clear negative for the oncology pipeline at a time when investors are already focused on the eventual Keytruda patent cliff and earlier disappointing 2026 guidance. Price has since churned between roughly 111.50 and 114.60 with no convincing reversal or follow-through, exactly the kind of action that whipsaws traders.

We've already cycled in and out of this name successfully this year—booking a nice gain from the mid-March entry at $115.68 to the 4/17 sale at $119.07—and there's no high-conviction setup right now for a fresh 7+ day hold. Longing here feels like catching a falling knife ahead of the 4/30 print, while shorting risks a snap-back bounce or positive surprise reaction given the stock's history of mixed post-earnings moves. Cash preserves capital until we see either a clean basing pattern or clearer post-earnings direction. The technical picture at daily granularity shows lower highs and the recent breakdown below the April consolidation, reinforcing that patience is the best risk-adjusted call with real money on the line. We'll reassess after the earnings volatility passes.